Ricolinostat
As of the edition of 20 October 2026, Ricolinostat is a small molecule: stopped in 2024; acts on HDAC6.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 11, 4 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Nervous system; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Ricolinostat.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HDAC6 | Protein deacetylase HDAC6 | Q9UBN7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 4 | 1 | 2 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2011 to now |
| Acetylon Pharmaceuticals | Lead sponsor of trials | 2014 to now |
| Regenacy Pharmaceuticals | Lead sponsor of trials | 2020 to now |
| 3E-Regenacy Pharmaceuticals | Lead sponsor of trials | 2022 to now |